|Bid||33.60 x 800|
|Ask||33.62 x 800|
|Day's Range||33.21 - 34.06|
|52 Week Range||26.81 - 56.25|
|Beta (5Y Monthly)||1.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jan 31, 2023 - Feb 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||73.92|
PASADENA, Calif., January 25, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Arrowhead...
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT On January 9, 2023, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced topline results for the Phase 2 SEQUOIA trial of fazirsiran (TAK-999/ARO-AAT) for the treatment of alpha-1 antitrypsin deficiency (AATD) liver disease. A copy of the slides discussing the results can be found here . The SEQUOIA trial is a placebo